These results demonstrated that increased expression of MYC, LARP1, ATG9B, and BCL2L11, as well as decreased expression of DPP4, GSTM2, ATP6V0E1, and STX12 were significantly correlated with poorer RFS and DFS outcomes in NSCLC patients. The gene discussed is GSTM2; the disease is non-small cell lung carcinoma.